These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
2. Comparison of metabolic abnormalities and clinical lipodystrophy 48 weeks after switching from HAART to Trizivir versus continued HAART: the Trizal study. Lafeuillade A; Clumeck N; Mallolas J; Jaeger H; Livrozet JM; Ferreira Mdo S; Johnson M; Cheret A; Antoun Z; HIV Clin Trials; 2003; 4(1):37-43. PubMed ID: 12577195 [TBL] [Abstract][Full Text] [Related]
3. Abacavir-lamivudine-zidovudine vs indinavir-lamivudine-zidovudine in antiretroviral-naive HIV-infected adults: A randomized equivalence trial. Staszewski S; Keiser P; Montaner J; Raffi F; Gathe J; Brotas V; Hicks C; Hammer SM; Cooper D; Johnson M; Tortell S; Cutrell A; Thorborn D; Isaacs R; Hetherington S; Steel H; Spreen W; JAMA; 2001 Mar; 285(9):1155-63. PubMed ID: 11231744 [TBL] [Abstract][Full Text] [Related]
4. Triple nucleoside treatment with abacavir plus the lamivudine/zidovudine combination tablet (COM) compared to indinavir/COM in antiretroviral therapy-naïve adults: results of a 48-week open-label, equivalence trial (CNA3014). Vibhagool A; Cahn P; Schechter M; Smaill F; Soto-Ramirez L; Carosi G; Montroni M; Pharo CE; Jordan JC; Thomas NE; Pearce G Curr Med Res Opin; 2004 Jul; 20(7):1103-14. PubMed ID: 15265255 [TBL] [Abstract][Full Text] [Related]
5. Efficacy, safety, and adherence with a twice-daily combination lamivudine/zidovudine tablet formulation, plus a protease inhibitor, in HIV infection. Eron JJ; Yetzer ES; Ruane PJ; Becker S; Sawyer GA; Fisher RL; Tolson JM; Shaefer MS AIDS; 2000 Apr; 14(6):671-81. PubMed ID: 10807190 [TBL] [Abstract][Full Text] [Related]
6. Twice-daily Trizivir versus Combivir-abacavir in antiretroviral-experienced adults with human immunodeficiency virus-1 infection: a formulation-switch trial. Fischl MA; Burnside AE; Farthing CE; Thompson MA; Bellos NC; Williams VC; Kauf TL; Wannamaker PG; Shaefer MS; Pharmacotherapy; 2003 Nov; 23(11):1432-40. PubMed ID: 14620390 [TBL] [Abstract][Full Text] [Related]
7. Pilot study of once-daily simplification therapy with abacavir/lamivudine/zidovudine and efavirenz for treatment of HIV-1 infection. Ruane P; Lang J; DeJesus E; Berger DS; Dretler R; Rodriguez A; Ward DJ; Lim ML; Liao Q; Reddy S; Clair MS; Vila T; Shaefer MS HIV Clin Trials; 2006; 7(5):229-36. PubMed ID: 17162316 [TBL] [Abstract][Full Text] [Related]
8. Predictors of optimal viral suppression in patients switched to abacavir, lamivudine, and zidovudine: the Swiss HIV Cohort Study. Wolbers M; Opravil M; von Wyl V; Hirschel B; Furrer H; Cavassini M; Vernazza P; Bernasconi E; Battegay M; Yerly S; Günthard H; Bucher HC; AIDS; 2007 Oct; 21(16):2201-7. PubMed ID: 18090047 [TBL] [Abstract][Full Text] [Related]
9. Abacavir/lamivudine/zidovudine maintenance after standard induction in antiretroviral therapy-naïve patients: FREE randomized trial interim results. Sprenger HG; Langebeek N; Mulder PG; Ten Napel CH; Vriesendorp R; Hoepelman AI; Legrand JC; Koopmans PP; Van Kasteren ME; Bravenboer B; Ten Kate RW; Groeneveld PH; van der Werf TS; Gisolf EH; Richter C AIDS Patient Care STDS; 2010 Jun; 24(6):361-6. PubMed ID: 20515418 [TBL] [Abstract][Full Text] [Related]
10. Compact quadruple therapy with the lamivudine/zidovudine combination tablet plus abacavir and efavirenz, followed by the lamivudine/zidovudine/abacavir triple nucleoside tablet plus efavirenz in treatment-naïve HIV-infected adults. Ruane PJ; Parenti DM; Margolis DM; Shepp DH; Babinchak TJ; Van Kempen AS; Kauf TL; Danehower SA; Yau L; Hessenthaler SM; Goodwin D; Hernandez JE; HIV Clin Trials; 2003; 4(4):231-43. PubMed ID: 12916008 [TBL] [Abstract][Full Text] [Related]
11. A prospective, 96-week study of the impact of Trizivir, Combivir/nelfinavir, and lamivudine/stavudine/nelfinavir on lipids, metabolic parameters and efficacy in antiretroviral-naive patients: effect of sex and ethnicity. Kumar PN; Rodriguez-French A; Thompson MA; Tashima KT; Averitt D; Wannamaker PG; Williams VC; Shaefer MS; Pakes GE; Pappa KA; HIV Med; 2006 Mar; 7(2):85-98. PubMed ID: 16420253 [TBL] [Abstract][Full Text] [Related]
12. Comparison of metabolic abnormalities 48 weeks after switching from highly active antiretroviral therapy containing a non-nucleoside reverse transcriptase inhibitor to Trizivir versus continued highly active antiretroviral therapy. Katlama C; Gazzard B; Mallolas J; Schürmann D; Moroni M; Demonty N; Antoun Z; Gordon D AIDS; 2003 Aug; 17(12):1855-6. PubMed ID: 12891074 [TBL] [Abstract][Full Text] [Related]
14. A dose-ranging study to evaluate the safety and efficacy of abacavir alone or in combination with zidovudine and lamivudine in antiretroviral treatment-naive subjects. Staszewski S; Katlama C; Harrer T; Massip P; Yeni P; Cutrell A; Tortell SM; Harrigan RP; Steel H; Lanier RE; Pearce G AIDS; 1998 Nov; 12(16):F197-202. PubMed ID: 9833847 [TBL] [Abstract][Full Text] [Related]
15. Simplification with abacavir-based triple nucleoside therapy versus continued protease inhibitor-based highly active antiretroviral therapy in HIV-1-infected patients with undetectable plasma HIV-1 RNA. Clumeck N; Goebel F; Rozenbaum W; Gerstoft J; Staszewski S; Montaner J; Johnson M; Gazzard B; Stone C; Athisegaran R; Moore S; AIDS; 2001 Aug; 15(12):1517-26. PubMed ID: 11504984 [TBL] [Abstract][Full Text] [Related]
16. A randomized controlled trial of single-class maintenance therapy with abacavir/lamivudine/zidovudine after standard triple antiretroviral induction therapy: final 96-week results from the FREE study. Sprenger HG; Langebeek N; Mulder PG; Ten Napel CH; Vriesendorp R; Hoepelman AI; Legrand JC; Koopmans PP; Bravenboer B; Ten Kate RW; Groeneveld P; Bierman W; van der Werf Ts; Gisolf E; Richter C HIV Med; 2015 Feb; 16(2):122-31. PubMed ID: 25472825 [TBL] [Abstract][Full Text] [Related]
17. Twice-daily triple nucleoside intensification treatment with lamivudine-zidovudine plus abacavir sustains suppression of human immunodeficiency virus type 1: results of the TARGET Study. Henry K; Wallace RJ; Bellman PC; Norris D; Fisher RL; Ross LL; Liao Q; Shaefer MS; J Infect Dis; 2001 Feb; 183(4):571-8. PubMed ID: 11170982 [TBL] [Abstract][Full Text] [Related]
18. Efficacy and safety of a quadruple combination Combivir + abacavir + efavirenz regimen in antiretroviral treatment-naive HIV-1-infected adults: La Francilienne. de Truchis P; Force G; Welker Y; Mechali D; Pulik M; Chemlal K; Rouveix E; Devidas A; Praindhui D; Mamet JP; J Acquir Immune Defic Syndr; 2002 Oct; 31(2):178-82. PubMed ID: 12394796 [TBL] [Abstract][Full Text] [Related]
19. Nevirapine/zidovudine/lamivudine has superior immunological and virological responses not reflected in clinical outcomes in a 48-week randomized comparison with abacavir/zidovudine/lamivudine in HIV-infected Ugandan adults with low CD4 cell counts. Munderi P; Walker AS; Kityo C; Babiker AG; Ssali F; Reid A; Darbyshire JH; Grosskurth H; Mugyenyi P; Gibb DM; Gilks CF; HIV Med; 2010 May; 11(5):334-44. PubMed ID: 20136661 [TBL] [Abstract][Full Text] [Related]
20. Lamivudine/abacavir maintains virological superiority over zidovudine/lamivudine and zidovudine/abacavir beyond 5 years in children. Green H; Gibb DM; Walker AS; Pillay D; Butler K; Candeias F; Castelli-Gattinara G; Compagnucci A; Della Negra M; de Rossi A; Feiterna-Sperling C; Giaquinto C; Harper L; Levy J; Saidi Y; Wintergerst U; AIDS; 2007 May; 21(8):947-55. PubMed ID: 17457088 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]